Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy

References

• Oelschlaeger TA. Bacteria as tumor therapeutics? Bioeng Bugs. 2010 Mar-Apr;1(2):146–147. PubMed PMID: 21326940; PubMed Central PMCID: PMCPMC3026455. DOI:10.4161/bbug.1.2.11248
   PubMedGoogle Scholar
• Parish CR. Cancer immunotherapy: the past, the present and the future[ast]. Immunol Cell Biol. 2003. 04. 81(2):106–113.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013 Dec;1836(2):187–196. PubMed PMID: 23748107. DOI:10.1016/j.bbcan.2013.05.003
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5. PubMed PMID: 23390376; PubMed Central PMCID: PMCPMC3559193.
   PubMedGoogle Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22;271(5256):1734–1736. PubMed PMID: 8596936.
   PubMed Web of Science ®Google Scholar
• Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015 Jan;27(1):3–10. PubMed PMID: 25038057. DOI:10.1093/intimm/dxu076
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616–622. PubMed PMID: 23295794; PubMed Central PMCID: PMCPMC4878048. DOI:10.1200/JCO.2012.44.6112
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723. PubMed PMID: 20525992; PubMed Central PMCID: PMCPMC3549297. DOI:10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Palmer SR, Erickson LA, Ichetovkin I, et al. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc. 2011; 86(10):981–990. PubMed PMID: PMC3184027. Doi:10.4065/mcp.2011.0287
   PubMed Web of Science ®Google Scholar
• Wilson KS, Kotb R. Is tremelimumab beneficial in advanced melanoma? J Clin Oncol. 2013 Aug 01;31(22):2835–2836. PubMed PMID: 23752103. DOI:10.1200/JCO.2013.49.6158
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond [10.1038/nrd2909]. Nat Rev Drug Discov. 2012. 04. 11(4):311–331.
   PubMed Web of Science ®Google Scholar
• Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015 Apr 27;112(19): 6140–6145. PubMed PMID: PMC4434760. DOI:10.1073/pnas.1417320112
   PubMed Web of Science ®Google Scholar
• Shuptrine C, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012 Jan 08;22(1):3–13. PubMed PMID: PMC3288558. DOI:10.1016/j.semcancer.2011.12.009
   PubMed Web of Science ®Google Scholar
• Stewart R, Hammond SA, Oberst M, et al. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer [journal article]. J Immunotherapy Cancer. 2014;2(1):29. DOI:10.1186/s40425-014-0029-x
   Google Scholar
• Schwartz LH, Litiere S, De Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016 Jul;62:132–137. PubMed PMID: 27189322. Doi:10.1016/j.ejca.2016.03.081
   PubMed Web of Science ®Google Scholar
• Chen TW, Razak AR, Bedard PL, et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.Ann Oncol. 2015 Sep;26(9):1824–1829. PubMed PMID: 25888611. DOI:10.1093/annonc/mdv182
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 02;373(1):23–34. PubMed PMID: 26027431. DOI:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Berman D, DePril V, et al., editors. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. ASCO Annual Meeting Proceedings; 2011.
   Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy [mdash] immune checkpoint blockade and associated endocrinopathies [Review]. Nat Rev Endocrinol. 2017 04;13(4):195–207. DOI:10.1038/nrendo.2016.205
   PubMed Web of Science ®Google Scholar
• Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688–696. DOI:10.1111/cup.12717
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016 [cited 2016 06 01];10(3):183–193. DOI:10.1177/1753465816636557
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391. DOI:10.1093/annonc/mdv383
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. Doi:10.1016/j.ctrv.2016.02.001
   PubMed Web of Science ®Google Scholar
• Kähler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14(7):662–681. DOI:10.1111/ddg.13047
   Web of Science ®Google Scholar
• Borghaei H, Brahmer J, Horn L, et al. P2.35: nivolumab vs docetaxel in advanced NSCLC: checkMate 017/057 2-Y Update and exploratory cytokine profile analysis: track: immunotherapy.J Thorac Oncol. 2016 Oct;11(10S):S237–S238. PubMed PMID: 27676569. DOI:10.1016/j.jtho.2016.08.106
   PubMedGoogle Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 09;373(2): 123–135. PubMed PMID: 26028407; PubMed Central PMCID: PMCPMC4681400. DOI:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17): 1627–1639. PubMed PMID: 26412456. DOI:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 09;387(10027): 1540–1550. PubMed PMID: 26712084. DOI:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19): 1823–1833. PubMed PMID: 27718847. DOI:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Socinski M, Creelan B, Horn L, et al. NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol. 2016;27(suppl_6):LBA7_PR-LBA7_PR. DOI:10.1093/annonc/mdw435.39
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016 Dec 12. PubMed PMID: 27979383. DOI:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07;387(10031): 1909–1920. PubMed PMID: 26952546. DOI:10.1016/S0140-6736(16)00561-4
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67–76. DOI:10.1016/S0140-6736(16)32455-2
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 05;373(19): 1803–1813. PubMed PMID: 26406148. DOI:10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19): 1856–1867. PubMed PMID: 27718784. DOI:10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.Lancet Oncol. 2016 Jul;17(7):956–965. PubMed PMID: 27247226. DOI:10.1016/S1470-2045(16)30066-3
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385. DOI:10.1016/S1470-2045(16)30364-3
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Lancet Oncol. 2016 Nov;17(11):1497–1508. PubMed PMID: 27745820. DOI:10.1016/S1470-2045(16)30498-3
   PubMed Web of Science ®Google Scholar
• Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. PubMed PMID: 27660705; PubMed Central PMCID: PMCPMC5028964. DOI:10.1186/s40425-016-0156-7
   PubMed Web of Science ®Google Scholar
• Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016 Jul;37(7):462–476. PubMed PMID: 27216414. DOI:10.1016/j.it.2016.04.010
   PubMed Web of Science ®Google Scholar
• Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016 Apr;15(4):235–247. PubMed PMID: 26965203. DOI:10.1038/nrd.2015.35
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015 Mar;93(3):290–296. PubMed PMID: 25367186; PubMed Central PMCID: PMCPMC4445461. DOI:10.1038/icb.2014.93
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 01;33(25): 2780–2788. 3377.PubMed PMID: 26014293. DOI:10.1200/JCO.2014.58
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial.Ann Surg Oncol. 2016 Dec;23(13):4169–4177. PubMed PMID: 27342831; PubMed Central PMCID: PMCPMC5090012. DOI:10.1245/s10434-016-5286-0
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Andtbacka RH, Collichio F, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016;9:7081–7093. PubMed PMID: 27895500; PubMed Central PMCID: PMCPMC5119624. DOI:10.2147/OTT.S115245
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, et al. CANCER IMMUNOLOGY. The “cancer immunogram”. Science. 2016 May 06;352(6286):658–660. PubMed PMID: 27151852. DOI:10.1126/science.aaf2834
   PubMed Web of Science ®Google Scholar
• Manson G, Norwood J, Marabelle A, et al. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27(7):1199–1206. DOI:10.1093/annonc/mdw181
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847–856. PubMed PMID: 25695955. DOI:10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016 Feb 02;114(3): 256–261. PubMed PMID: 26794281; PubMed Central PMCID: PMCPMC4742588. DOI:10.1038/bjc.2015.467
   PubMed Web of Science ®Google Scholar
• Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016;4:3. PubMed PMID: 26788324; PubMed Central PMCID: PMCPMC4717548. DOI:10.1186/s40425-016-0107-3
   PubMed Web of Science ®Google Scholar
• Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy [journal article]. J Immunotherapy Cancer. 2016;4(1):3. DOI:10.1186/s40425-016-0107-3
   PubMed Web of Science ®Google Scholar